A Phase III trial (OlympiA) showed the usefulness of postoperative addition of olaparib, a PARP inhibitor, in patients with germline BRCA1/2 pathogenic variant-positive breast cancer with a high risk of recurrence who completed neoadjuvant/adjuvant chemotherapy [12, 42]. This evidence concerns the gene BRCA1 and breast cancer.